IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v37y2019i11d10.1007_s40273-019-00819-z.html
   My bibliography  Save this article

Transparency in Decision Modelling: What, Why, Who and How?

Author

Listed:
  • Christopher James Sampson

    (Office of Health Economics)

  • Renée Arnold

    (Arnold Consultancy & Technology, LLC)

  • Stirling Bryan

    (University of British Columbia)

  • Philip Clarke

    (University of Oxford)

  • Sean Ekins

    (Collaborations Pharmaceuticals Inc.)

  • Anthony Hatswell

    (Delta Hat)

  • Neil Hawkins

    (University of Glasgow)

  • Sue Langham

    (Maverex Limited)

  • Deborah Marshall

    (University of Calgary)

  • Mohsen Sadatsafavi

    (University of British Columbia)

  • Will Sullivan

    (BresMed Health Solutions)

  • Edward C. F. Wilson

    (University of East Anglia)

  • Tim Wrightson

    (Adis International Limited)

Abstract

Transparency in decision modelling is an evolving concept. Recently, discussion has moved from reporting standards to open-source implementation of decision analytic models. However, in the debate about the supposed advantages and disadvantages of greater transparency, there is a lack of definition. The purpose of this article is not to present a case for or against transparency, but rather to provide a more nuanced understanding of what transparency means in the context of decision modelling and how it could be addressed. To this end, we review and summarise the discourse to date, drawing on our collective experience. We outline a taxonomy of the different manifestations of transparency, including reporting standards, reference models, collaboration, model registration, peer review and open-source modelling. Further, we map out the role and incentives for the various stakeholders, including industry, research organisations, publishers and decision makers. We outline the anticipated advantages and disadvantages of greater transparency with respect to each manifestation, as well as the perceived barriers and facilitators to greater transparency. These are considered with respect to the different stakeholders and with reference to issues including intellectual property, legality, standards, quality assurance, code integrity, health technology assessment processes, incentives, funding, software, access and deployment options, data protection and stakeholder engagement. For each manifestation of transparency, we discuss the ‘what’, ‘why’, ‘who’ and ‘how’. Specifically, their meaning, why the community might (or might not) wish to embrace them, whose engagement as stakeholders is required and how relevant objectives might be realised. We identify current initiatives aimed to improve transparency to exemplify efforts in current practice and for the future.

Suggested Citation

  • Christopher James Sampson & Renée Arnold & Stirling Bryan & Philip Clarke & Sean Ekins & Anthony Hatswell & Neil Hawkins & Sue Langham & Deborah Marshall & Mohsen Sadatsafavi & Will Sullivan & Edward , 2019. "Transparency in Decision Modelling: What, Why, Who and How?," PharmacoEconomics, Springer, vol. 37(11), pages 1355-1369, November.
  • Handle: RePEc:spr:pharme:v:37:y:2019:i:11:d:10.1007_s40273-019-00819-z
    DOI: 10.1007/s40273-019-00819-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-019-00819-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-019-00819-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Garret Christensen & Edward Miguel, 2018. "Transparency, Reproducibility, and the Credibility of Economics Research," Journal of Economic Literature, American Economic Association, vol. 56(3), pages 920-980, September.
    2. Sabina Sanghera & Emma Frew & Tracy Roberts, 2015. "Adapting the CHEERS Statement for Reporting Cost-Benefit Analysis," PharmacoEconomics, Springer, vol. 33(5), pages 533-534, May.
    3. Geert W. J. Frederix, 2019. "Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations," PharmacoEconomics - Open, Springer, vol. 3(4), pages 433-435, December.
    4. Daniels, Norman & Sabin, James E., 2002. "Setting Limits Fairly: Can we learn to share medical resources?," OUP Catalogue, Oxford University Press, number 9780195149364.
    Full references (including those not matched with items on IDEAS)

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Chris Sampson’s journal round-up for 9th March 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-03-09 12:00:00

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Kai Jia & Nan Zhang, 2022. "Categorization and eccentricity of AI risks: a comparative study of the global AI guidelines," Electronic Markets, Springer;IIM University of St. Gallen, vol. 32(1), pages 59-71, March.
    2. Harvard, Stephanie & Werker, Gregory R. & Silva, Diego S., 2020. "Social, ethical, and other value judgments in health economics modelling," Social Science & Medicine, Elsevier, vol. 253(C).
    3. Josh J. Carlson & Surrey M. Walton & Anirban Basu & Richard H. Chapman & Jonathan D. Campbell & R. Brett McQueen & Steven D. Pearson & Daniel R. Touchette & David Veenstra & Melanie D. Whittington & D, 2019. "Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States," PharmacoEconomics, Springer, vol. 37(11), pages 1321-1327, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bruno Ferman & Cristine Pinto & Vitor Possebom, 2020. "Cherry Picking with Synthetic Controls," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 39(2), pages 510-532, March.
    2. Alexander Frankel & Maximilian Kasy, 2022. "Which Findings Should Be Published?," American Economic Journal: Microeconomics, American Economic Association, vol. 14(1), pages 1-38, February.
    3. Cappelen, Alexander W. & Norheim, Ole Frithjof, 2006. "Responsibility, fairness and rationing in health care," Health Policy, Elsevier, vol. 76(3), pages 312-319, May.
    4. Bensch, Gunther & Gotz, Gunnar & Peters, Jörg, 2020. "Effects of rural electrification on employment: A comment on Dinkelman (2011)," Ruhr Economic Papers 840, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.
    5. Stefano DellaVigna & Elizabeth Linos, 2022. "RCTs to Scale: Comprehensive Evidence From Two Nudge Units," Econometrica, Econometric Society, vol. 90(1), pages 81-116, January.
    6. Stanley, T. D. & Doucouliagos, Chris, 2019. "Practical Significance, Meta-Analysis and the Credibility of Economics," IZA Discussion Papers 12458, Institute of Labor Economics (IZA).
    7. Bruns, Stephan & Herwartz, Helmut & Ioannidis, John P.A. & Islam, Chris-Gabriel & Raters, Fabian H. C., 2023. "Statistical reporting errors in economics," MetaArXiv mbx62, Center for Open Science.
    8. Christian Dippel & Robert Gold & Stephan Heblich & Rodrigo Pinto, 2017. "Instrumental Variables and Causal Mechanisms: Unpacking the Effect of Trade on Workers and Voters," CESifo Working Paper Series 6816, CESifo.
    9. Andor, Mark A. & Gerster, Andreas & Peters, Jörg & Schmidt, Christoph M., 2020. "Social Norms and Energy Conservation Beyond the US," Journal of Environmental Economics and Management, Elsevier, vol. 103(C).
    10. Christopher Snyder & Ran Zhuo, 2018. "Sniff Tests as a Screen in the Publication Process: Throwing out the Wheat with the Chaff," NBER Working Papers 25058, National Bureau of Economic Research, Inc.
    11. Andrew Y Chen & Tom Zimmermann & Jeffrey Pontiff, 2020. "Publication Bias and the Cross-Section of Stock Returns," The Review of Asset Pricing Studies, Society for Financial Studies, vol. 10(2), pages 249-289.
    12. Askildsen, Jan Erik & Holmås, Tor Helge & Kaarboe, Oddvar, 2010. "Prioritization and patients' rights: Analysing the effect of a reform in the Norwegian hospital sector," Social Science & Medicine, Elsevier, vol. 70(2), pages 199-208, January.
    13. Sofaer, Neema & Kapiriri, Lydia & Atuyambe, Lynn M. & Otolok-Tanga, Erasmus & Norheim, Ole Frithjof, 2009. "Is the selection of patients for anti-retroviral treatment in Uganda fair?: A qualitative study," Health Policy, Elsevier, vol. 91(1), pages 33-42, June.
    14. Doucouliagos, Hristos & Paldam, Martin & Stanley, T.D., 2018. "Skating on thin evidence: Implications for public policy," European Journal of Political Economy, Elsevier, vol. 54(C), pages 16-25.
    15. Eibich, Peter & Goldzahl, Léontine, 2021. "Does retirement affect secondary preventive care use? Evidence from breast cancer screening," Economics & Human Biology, Elsevier, vol. 43(C).
    16. Bauer, Michal & Chytilová, Julie & Miguel, Edward, 2020. "Using survey questions to measure preferences: Lessons from an experimental validation in Kenya," European Economic Review, Elsevier, vol. 127(C).
    17. Garret Christensen & Allan Dafoe & Edward Miguel & Don A Moore & Andrew K Rose, 2019. "A study of the impact of data sharing on article citations using journal policies as a natural experiment," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-13, December.
    18. Patrick Vu, 2022. "Can the Replication Rate Tell Us About Publication Bias?," Papers 2206.15023, arXiv.org, revised Jul 2022.
    19. Christian Dippel & Michael Poyker, 2019. "How Common are Electoral Cycles in Criminal Sentencing?," NBER Working Papers 25716, National Bureau of Economic Research, Inc.
    20. Rhiannon Tudor Edwards & Catherine Louise Lawrence, 2021. "‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 653-664, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:37:y:2019:i:11:d:10.1007_s40273-019-00819-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.